FDA rescinds Marketing Denial Order on TPB vapor products; products remain under review

Turning Point Brands, Inc.

On Oct 7, FDA rescinded its Sept 14 Marketing Denial Order for certain TPB vapor products, citing need for further review.
All proprietary vapor products (incl. Solace e-liquids) will continue marketing while PMTAs remain under FDA review.
TPB withdrew its petition for review and motion to stay filed with the 6th Circuit following the rescission.
CEO Larry Wexler expressed encouragement and reiterated commitment to evidence-based PMTA process.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.